Jonathan C Javitt insider trades: NRX Pharmaceuticals (NRXP) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jonathan reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 17, 2024 | NRXP | ↑ Buy | 40,000 | $1.17 | $47K | Direct | Dec 18, 2024 (1d) |
| Aug 23, 2023 | NRXP | ↑ Buy | 100,000 | $0.33 | $33K | Direct | Aug 24, 2023 (1d) |
| Aug 22, 2023 | NRXP | ↑ Buy | 200,000 | $0.32 | $64K | Direct | Aug 23, 2023 (1d) |
| Dec 7, 2022 | NRXP | ↓ Sell | 400,000 | $1.00 | $400K | By Trust | Dec 9, 2022 (2d) |
| Jun 1, 2022 | NRXP | ↑ Buy | 100,000 | $58.00 | $5.8M | Direct | Jun 2, 2022 (1d) |
| Aug 27, 2008 | BCLI | ↓ Sell | 40,000 | $0.25 | $10K | Direct | Aug 28, 2008 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Jonathan C Javitt's insider trades
Jonathan C Javitt is CEO and Chairman at NRX Pharmaceuticals (NRXP). Since Aug 27, 2008, Jonathan has reported 4 open-market purchases worth $5.9M and 2 sales worth $410K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (4 filings), option exercises (2 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NRXP insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.